DETROIT, MI, SciTech Development, a clinical-stage oncology company, announced the successful close of its Convertible Note Round at $5.5 million.
SciTech Development, a clinical-stage oncology company advancing its innovative nanotechnology-enabled cancer drug, announced the successful close of its Convertible Note Round #3 (CNR 3) at $5.5 million. The round, which officially closed on September 5, 2025, surpassed its original $3.0 million target by $2.5 million.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
